Your browser doesn't support javascript.
loading
Monitoring and evaluation of breast cancer screening programmes: selecting candidate performance indicators.
Muratov, Sergei; Canelo-Aybar, Carlos; Tarride, Jean-Eric; Alonso-Coello, Pablo; Dimitrova, Nadya; Borisch, Bettina; Castells, Xavier; Duffy, Stephen W; Fitzpatrick, Patricia; Follmann, Markus; Giordano, Livia; Hofvind, Solveig; Lebeau, Annette; Quinn, Cecily; Torresin, Alberto; Vialli, Claudia; Siesling, Sabine; Ponti, Antonio; Giorgi Rossi, Paolo; Schünemann, Holger; Nyström, Lennarth; Broeders, Mireille.
Afiliação
  • Muratov S; Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Canelo-Aybar C; Iberoamerican Cochrane Center, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau-CIBERESP), Barcelona, Spain.
  • Tarride JE; Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
  • Alonso-Coello P; Iberoamerican Cochrane Center, Instituto de Investigación Biomédica Sant Pau (IIB Sant Pau-CIBERESP), Barcelona, Spain.
  • Dimitrova N; European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, Ispra, VA, Italy. Nadya.Dimitrova@ec.europa.eu.
  • Borisch B; Institute of Global Health, University of Geneva, Geneva, Switzerland.
  • Castells X; IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Duffy SW; Queen Mary University of London, London, UK.
  • Fitzpatrick P; National Screening Service, Dublin, Ireland.
  • Follmann M; UCD School of Public Health, Physiotherapy & Sports Science, Dublin, Ireland.
  • Giordano L; German Cancer Society, Berlin, Germany.
  • Hofvind S; CPO-Piedmont - AOU Città della Salute e della Scienza, Torino, Italy.
  • Lebeau A; Cancer Registry of Norway, Oslo, Norway.
  • Quinn C; University Medical Center Hamburg-Eppendorf and Private Group Practice for Pathology, Hamburg, Germany.
  • Torresin A; St. Vincent's University Hospital, Dublin, Ireland.
  • Vialli C; ASST Grande Ospedale Metropolitano, Milan, Italy.
  • Siesling S; European Commission, Joint Research Centre, Via E. Fermi 2749 - TP 127, I-21027, Ispra, VA, Italy.
  • Ponti A; Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, Netherlands.
  • Giorgi Rossi P; University of Twente, Enschede, Netherlands.
  • Schünemann H; CPO-Piedmont - AOU Città della Salute e della Scienza, Torino, Italy.
  • Nyström L; AUSL Reggio Emilia, IRCCS, Reggio Emilia, Italy.
  • Broeders M; Department of Health Research Methods, Evidence, and Impact, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
BMC Cancer ; 20(1): 795, 2020 Aug 24.
Article em En | MEDLINE | ID: mdl-32831048
BACKGROUND: In the scope of the European Commission Initiative on Breast Cancer (ECIBC) the Monitoring and Evaluation (M&E) subgroup was tasked to identify breast cancer screening programme (BCSP) performance indicators, including their acceptable and desirable levels, which are associated with breast cancer (BC) mortality. This paper documents the methodology used for the indicator selection. METHODS: The indicators were identified through a multi-stage process. First, a scoping review was conducted to identify existing performance indicators. Second, building on existing frameworks for making well-informed health care choices, a specific conceptual framework was developed to guide the indicator selection. Third, two group exercises including a rating and ranking survey were conducted for indicator selection using pre-determined criteria, such as: relevance, measurability, accurateness, ethics and understandability. The selected indicators were mapped onto a BC screening pathway developed by the M&E subgroup to illustrate the steps of BC screening common to all EU countries. RESULTS: A total of 96 indicators were identified from an initial list of 1325 indicators. After removing redundant and irrelevant indicators and adding those missing, 39 candidate indicators underwent the rating and ranking exercise. Based on the results, the M&E subgroup selected 13 indicators: screening coverage, participation rate, recall rate, breast cancer detection rate, invasive breast cancer detection rate, cancers > 20 mm, cancers ≤10 mm, lymph node status, interval cancer rate, episode sensitivity, time interval between screening and first treatment, benign open surgical biopsy rate, and mastectomy rate. CONCLUSION: This systematic approach led to the identification of 13 BCSP candidate performance indicators to be further evaluated for their association with BC mortality.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Programas de Rastreamento / Indicadores de Qualidade em Assistência à Saúde / Detecção Precoce de Câncer / Implementação de Plano de Saúde Tipo de estudo: Diagnostic_studies / Evaluation_studies / Guideline / Prognostic_studies / Qualitative_research / Screening_studies / Sysrev_observational_studies Limite: Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Programas de Rastreamento / Indicadores de Qualidade em Assistência à Saúde / Detecção Precoce de Câncer / Implementação de Plano de Saúde Tipo de estudo: Diagnostic_studies / Evaluation_studies / Guideline / Prognostic_studies / Qualitative_research / Screening_studies / Sysrev_observational_studies Limite: Aged / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Revista: BMC Cancer Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Canadá